Literature DB >> 371544

Chloroquine resistance in malaria: accessibility of drug receptors to mefloquine.

C D Fitch, R L Chan, R Chevli.   

Abstract

The process of mefloquine accumulation was studied in mouse erythrocytes infected with either Plasmodium berghei CS (chloroquine susceptible) or P. berghei CR (chloroquine resistant). In both cases, mefloquine was accumulated by a saturable process with an apparent dissociation constant of 2.5 x 10(-6) M and an apparent maximal capacity of 700 mumol per kg of erythrocyte pellet; uninfected mouse erythrocytes accumulated more than half as much mefloquine as infected erythrocytes. The process of accumulation was not stimulated by providing glucose as a substrate, and it was not inhibited in infected erythrocytes by azide, iodoacetate, or incubation at 2 degrees C. Although mefloquine was accumulated more effectively than chloroquine by uninfected erythrocytes and by erythrocytes infected with P. berghei CR, competition between chloroquine and mefloquine was observed, raising the possibility that the same process of accumulation serves both drugs. Chloroquine competitively inhibits mefloquine accumulation, with an apparent inhibitor constant of 1.7 x 10(-3) M, and mefloquine competitively inhibits chloroquine accumulation, with an apparent inhibitor constant of 2 x 10(-6) M. The same process of accumulation and the same group of receptors could serve both drugs if mefloquine has greater access than chloroquine to the receptors. Regardless of whether the same process serves both drugs, undiminished accumulation by erythrocytes infected with P. berghei CR provides an explanation for the superiority of mefloquine in treating chloroquine-resistant malaria.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 371544      PMCID: PMC352643          DOI: 10.1128/AAC.15.2.258

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Molecular structural effects involved in the interaction of quinolinemethanolamines with DNA. Implications for antimalarial action.

Authors:  M W Davidson; B G Griggs; D W Boykin; W D Wilson
Journal:  J Med Chem       Date:  1977-09       Impact factor: 7.446

2.  Chloroquine susceptibility in malaria: dependence on exposure of parasites to the drug.

Authors:  C D Fitch
Journal:  Life Sci       Date:  1977-11-15       Impact factor: 5.037

3.  Chloroquine accumulation by erythrocytes: a latent capability.

Authors:  C D Fitch; R Chevli; Y Gonzalez
Journal:  Life Sci       Date:  1974-06-16       Impact factor: 5.037

4.  Infections with Plasmodium falciparum and Plasmodium vivax in the owl monkey--model systems for basic biological and chemotherapeutic studies.

Authors:  L H Schmidt
Journal:  Trans R Soc Trop Med Hyg       Date:  1973       Impact factor: 2.184

5.  Antimalarial activities of various 4-quinolonemethanols with special attention to WR-142,490 (mefloquine).

Authors:  L H Schmidt; R Crosby; J Rasco; D Vaughan
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

6.  Sequential treatment with quinine and mefloquine or quinine and pyrimethamine-sulfadoxine for falciparum malaria.

Authors:  A P Hall; E B Doberstyn; C Karnchanachetanee; S Samransamruajkit; B Laixuthai; E J Pearlman; R M Lampe; C F Miller; P Phintuyothin
Journal:  Br Med J       Date:  1977-06-25

7.  Erythrocyte surface: novel determinant of drug susceptibility in rodent malaria.

Authors:  C D Fitch; R C Ng; R Chevli
Journal:  Antimicrob Agents Chemother       Date:  1978-08       Impact factor: 5.191

8.  Activities of various 4-aminoquinolines against infections with chloroquine-resistant strains of Plasmodium falciparum.

Authors:  L H Schmidt; D Vaughan; D Mueller; R Crosby; R Hamilton
Journal:  Antimicrob Agents Chemother       Date:  1977-05       Impact factor: 5.191

9.  The chemotherapy of rodent malaria, XXVII. Studies on mefloquine (WR 142,490).

Authors:  W Peters; R E Howells; J Portus; B L Robinson; S Thomas; D C Warhurst
Journal:  Ann Trop Med Parasitol       Date:  1977-12

10.  High-affinity accumulation of chloroquine by mouse erythrocytes infected with Plasmodium berghei.

Authors:  C D Fitch; N G Yunis; R Chevli; Y Gonzalez
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

View more
  7 in total

1.  Binding of antimalarial drugs to hemozoin from Plasmodium berghei.

Authors:  A Jearnpipatkul; P Govitrapong; Y Yuthavong; P Wilairat; B Panijpan
Journal:  Experientia       Date:  1980-09-15

2.  Investigation of the in vitro gender-specific partitioning of mefloquine in malarial infected red blood cells and plasma.

Authors:  Nongluk Seethorn; Walther H Wernsdorfer; Harald Noedl; Juntra Karbwang; Kesara Na-Bangchang
Journal:  Am J Trop Med Hyg       Date:  2013-09-03       Impact factor: 2.345

Review 3.  Clinical pharmacokinetics of mefloquine.

Authors:  J Karbwang; N J White
Journal:  Clin Pharmacokinet       Date:  1990-10       Impact factor: 6.447

Review 4.  Clinical pharmacokinetics of antimalarial drugs.

Authors:  N J White
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

5.  The antimalarial drug mefloquine binds to membrane phospholipids.

Authors:  R Chevli; C D Fitch
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

6.  Plasma and whole blood mefloquine concentrations during treatment of chloroquine-resistant falciparum malaria with the combination mefloquine-sulphadoxine-pyrimethamine.

Authors:  J Karbwang; S Looareesuwan; R E Phillips; Y Wattanagoon; M E Molyneux; B Nagachinta; D J Back; D A Warrell
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

Review 7.  Complex Membrane Channel Blockade: A Unifying Hypothesis for the Prodromal and Acute Neuropsychiatric Sequelae Resulting from Exposure to the Antimalarial Drug Mefloquine.

Authors:  Jane C Quinn
Journal:  J Parasitol Res       Date:  2015-10-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.